tirzepatide and kidney issues (Zepbound) showed improved function in obese patients with both chronic kidney disease #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https Zepbound and Kidney Disease: Safety

The SURMOUNT trials demonstrated average weight loss of 22.5% at this level, with 63% of participants losing at least 20% of their body weight

Further, some employers may exclude semaglutide or any weight loss treatments from their formularies, regardless of publicly-available coverage policies

There is no specific time frame

Achieve up to 20% body weight reduction with Wegovy and you may also see improvements in the following: In the STEP 1 trial, people using Wegovy saw greater reductions in systolic blood pressure compared to those on placebo with an average drop of 6.2 mmHg vs 1.1 mmHg. Treatment with Wegovy led to greater improvements in cholesterol measures, including reductions in total cholesterol, LDL ("bad" cholesterol), and triglycerides. By supporting weight loss and improving key health markers including waist circumference with a 5.7-inch (14.5cm) reduction vs 2-inch (5cm) reduction with placebo